Antibodies Know Right From Left

May 18, 1998

Knowing right from left is essential in many areas of life -- even on the molecular level. Prof. Meir Wilchek of the Weizmann Institute's Biological Chemistry Department, working with an international team of researchers, has now discovered that this ability is particularly prominent in antibodies, the Y-shaped proteins produced by the immune system.

Antibodies fight disease-causing intruders, such as viruses, by binding with the intruders' molecules and thus neutralizing them. In a study reported in the April 8 issue of the Journal of the American Chemical Society, the scientists found that in seeking out appropriate molecules with which to bind, the antibodies distinguish between left- and right-handed amino acids, the building blocks of proteins. Thus, some antibodies only bind with left-handed amino acids, completely ignoring the right-handed ones, while others only bind with right-handed amino acids.

The antibodies are so exquisitely precise they can recognize a small part of a single amino acid, known as the chiral center, which determines the amino acid's orientation to the right or left. Molecules that are identical in chemical composition but whose structures are mirror images of one another, like the right and left hand, are called chiral (from chir, Ancient Greek for "hand"). Such molecules have different properties and are not superimposable.

This research may prove of great significance for the pharmaceutical industry. It has been shown in the past few years that in many drugs it is only the compound of a particular "handedness" that is effective, while its "mirror image" is useless or even harmful. Therefore, developing an efficient way to identify and sort out left- and right-handed molecules with the help of antibodies could pave the way for more effective pharmaceuticals.

Prof. Wilchek serves as Dean of the Biochemistry Faculty and holds the Marc R. Gutwirth Chair of Molecular Biology. He conducted the study with Oliver Hofstetter (recipient of a short-term fellowship from Boehringer Ingelheim Funds) and Dr. Heike Hofstetter of Weizmann's Biological Chemistry Department, Prof. Volke Schurig of Germany's Tuebingen University and Prof. Bernard S. Green of the Hebrew University of Jerusalem. Funding was provided by the German-Israeli Foundation for Scientific Research and Development (GIF).

The Weizmann Institute of Science, in Rehovot, Israel, is one of the world's foremost centers of scientific research and graduate study. Its 2,400 scientists, students, technicians, and engineers pursue basic research in the quest for knowledge and the enhancement of the human condition. New ways of fighting disease and hunger, protecting the environment, and harnessing alternative sources of energy are high priorities.

Weizmann Institute news releases are posted on the World Wide Web at and also at

American Committee for the Weizmann Institute of Science

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to